Koschmann Carl, Nunez Felipe J, Mendez Flor, Brosnan-Cashman Jacqueline A, Meeker Alan K, Lowenstein Pedro R, Castro Maria G
Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of Michigan Medical School, Ann Arbor, Michigan.
Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan.
Cancer Res. 2017 Jan 15;77(2):227-233. doi: 10.1158/0008-5472.CAN-16-2301. Epub 2017 Jan 6.
Genes encoding proteins that regulate chromatin structure and DNA modifications [i.e., chromatin regulatory factors (CRF)] and genes encoding histone proteins harbor recurrent mutations in most human cancers. These mutations lead to modifications in tumor chromatin and DNA structure and an altered epigenetic state that contribute to tumorigenesis. Mutated CRFs have now been identified in most types of cancer and are increasingly regarded as novel therapeutic targets. In this review, we discuss DNA alterations in CRFs and how these influence tumor chromatin structure and function, which in turn leads to tumorigenesis. We also discuss the clinical implications and review concepts of targeted treatments for these mutations. Continued research on CRF mutations will be critical for our future understanding of cancer biology and the development and implementation of novel cancer therapies. Cancer Res; 77(2); 227-33. ©2017 AACR.
在大多数人类癌症中,编码调节染色质结构和DNA修饰的蛋白质的基因[即染色质调节因子(CRF)]以及编码组蛋白的基因存在反复突变。这些突变导致肿瘤染色质和DNA结构的改变以及表观遗传状态的改变,从而促进肿瘤发生。现已在大多数癌症类型中鉴定出突变的CRF,并且它们越来越被视为新的治疗靶点。在本综述中,我们讨论了CRF中的DNA改变以及这些改变如何影响肿瘤染色质的结构和功能,进而导致肿瘤发生。我们还讨论了这些突变的临床意义,并综述了针对这些突变的靶向治疗概念。对CRF突变的持续研究对于我们未来理解癌症生物学以及开发和实施新型癌症治疗至关重要。癌症研究;77(2);227 - 33。©2017美国癌症研究协会。